Oregon is a leader in promoting healthcare price transparency with a state-run APCD, Oregon All Payer All Claims Database (APAC), and comprehensive mandatory reporting statues for hospitals and other facilities (see 2017 use case document). Oregon is also experimenting with health delivery and payment reform, directing various state agencies to conduct studies on the feasibility of alternative health care delivery financing and coordinated care models that reward quality over volume of patients.
In 2019, the Oregon Legislature is focusing on fighting the rising cost of prescription drugs. With more than 25 bills introduced which touch on pharmaceuticals, Oregon is considering a wide range of solutions, including importing drugs wholesale from Canada (HB 2689), reviewing prices and establishing price caps (HB 2696), reimbursing patients for overly expensive drugs (HB 2424), and publishing drug plans (HB 2692). There is also a Democratic bill in the Senate which would establish a single payer system (SB 770), and a bill which prohibits surprise balance billing (HB 2701).
In the 2018 legislative term, Oregon enacted the “Prescription Drug Price Transparency Act” (HB4005), which is fairly similar to what has become law in a few other states. When the price of a medicine rises more than 10 percent, a drug maker must report the reasons to the Oregon Department of Consumer and Business Services, including information about cost of production, marketing and research. Manufacturers face civil penalties of up to $10,000 per day for failing to comply. In addition to mandating new disclosures by drugmakers and insurers, the new law creates a task force that will develop a strategy for greater transparency across the entire supply chain of pharmaceutical products.
The State Database
The Source tracks state activities impacting healthcare price and competition in both legislation and litigation in a searchable database to help stakeholders at the state level understand their legal and regulatory environment as they make efforts to improve access, quality, and efficiency, and reduce costs in healthcare.
LEGISLATION: The Database of State Laws Impacting Healthcare Cost and Quality (SLIHCQ), created by The Source on Healthcare Price & Competition and Catalyst for Payment Reform, catalogues state legislation governing price transparency, provider market power, provider payment, provider networks, and benefit design. The database also includes pharmaceutical legislation beginning in the 2017-2018 legislative session. *Note: Current legislative session bill updates are ongoing. Check back weekly for updates.
LITIGATION: The Source tracks major litigation and antitrust enforcement action by federal entities (FTC or DOJ), state attorney generals, and private parties in the main provider and insurer markets, particularly legal challenges of healthcare consolidation and anticompetitive contract provisions. Additionally, the database contains major pharmaceutical cases including legislation challenges and significant appellate cases.
Search the database across all jurisdictions on the State Overview page, or view and filter existing legislation or litigation on individual state pages. The database allows customized search and filter by keyword, status, and/or key issue category. *Multiple filter/selections enabled. Click here for User Guide.
LEGISLATIVE CALENDAROregon’s current legislative term runs from 1/22/2019 – 6/30/2019. Oregon’s next legislative term will begin in 2020.
2017 – 2019 BUDGETThe biennium budget begins on July 1 of an odd-numbered year and ends on June 30 of the next odd-numbered year. The Governor is expected to sign the 2019-2021 Budget at the end of June 2019. To view the Governor’s most recent proposal on Oregon’s health spending, click here.
- Oregon was one of 16 states to file an amicus brief supporting the FTC’s winning position in the Ninth Circuit appeal of St. Luke’s Health Care Sys. v. FTC, No. 14-35173 (March 7, 2014), decided February 10, 2015. The States’ brief stated that the acceleration of health care costs due to the growth of large health care provider systems had become a matter of grave concern for the states.